ExThera’s proprietary Seraph 100 Microbind Affinity Blood Filter (Seraph 100) is a first-of-its kind, CE Marked, technology designed to reduce bloodborne pathogens during bloodstream infections. Validated in preclinical studies and in a clinical trial in Europe, the device promises to address significant unmet needs for immediate treatment, even before the pathogen is identified.
Seraph’s broad-spectrum ability to reduce the pathogen bioburden without harming the treated blood gives it many potential clinical applications. The company has evaluated the therapeutic use of Seraph 100 in a dialysis-like extracorporeal circuit for treating patients with both drug-resistant and drug-susceptible bloodstream infections.
Watch viedo here
Women's Health Community Supported by Hologic
Comprehensive information on women’s health issues and management, management and personalisation.
Enterprise Imaging Community
Advanced and scalable radiology solutions that can help improve care coordination, increase speed and facilitate accurate clinical decisions.
Decision Support Community Supported by Siemens Healthineers
Leading the way in highlighting useful and efficient decision support tools for improved patient outcomes.
Sepsis Community Supported by Abionic
Addressing the latest developments in sepsis and providing clinically useful information for diagnosis and treatment of patients.
New Study Shows Telemedicine Has Clear Benefits for Patients
Telemedicine was the most cost-effective and safest solution to offering... Read more
Machine Learning Tool Helps Hospitals Reduce Risk of COVID-19
A machine learning tool has been created to help predict patients at high... Read more
Foetal Brain Development Impacted by Maternal Stress During COVID-19 Pandemic
The COVID-19 pandemic created many disruptions to everyday life, including disr Read more
JOIN OUR MANAGEMENT COMMUNITY